Granted Patent B2

US 8,889,698 · App. 13/243,776 · Granted Nov 18, 2014

Abstract

Claims (219)

1. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula II:

wherein:

X is N;

Y is CO;

R 1 and R 3 are each independently selected from alkoxy, alkyl, amino, halogen, and hydrogen;

R 2 is selected from alkoxy, alkyl, alkenyl, alkynyl, amide, amino, halogen, and hydrogen;

R 6 and R 8 are each independently selected from alkyl, alkoxy, amino, halogen, and hydrogen;

R 5 and R 9 are each hydrogen;

R 7 is selected from amino, amide, alkyl, hydroxyl, and alkoxy;

R 10 is hydrogen;

each W is independently selected from C and N, wherein if W is N, then p is 0 or 1, and if W is C, then p is 1;

for W—(R 10 ) p , W is N and p is 1;

for W—(R 7 ) p , W is C and p is 1;

for W—(R 4 ) p , W is C, p is 1 and R 4 is H, or W is N and p is 0;

Z 1 is a double bond, and Z 2 and Z 3 are each a single bond;

with the proviso that if R 1 is hydrogen, then R 3 is alkoxy;

with the proviso that if R 3 is hydrogen, then R 1 is selected from amino and alkoxy;

with the proviso that if R 7 is selected from alkyl, hydroxyl, and alkoxy, then at least one of R 6 and R 8 is independently selected from alkyl, alkoxy, amino, and halogen;

or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1 , wherein R 7 is amino.

3. The method according to claim 2 , wherein the compound of Formula II is 2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one.

4. The method according to claim 1 , wherein R 7 is selected from hydroxyl and alkoxy.

5. The method according to claim 4 , wherein the compound of Formula II is selected from:

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)methanesulfonamide;

2-(4-hydroxy-3-methylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3-methylphenyI)-5,7-dimethoxyquinazolin-4(3H)-one; and

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one.

6. The method according to claim 4 , wherein R 6 and R 8 are each independently alkyl;

R 2 is hydrogen; and

R 7 is selected from hydroxyl and alkoxy substituted with a hydroxyl.

7. The method according to claim 6 , wherein the compound of Formula II is 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one.

8. The method according to claim 1 , wherein R 7 is an amino or an alkoxy selected from the group represented by Formula III:

wherein:

A is selected from O and N;

n is selected from 0, 1, 2, 3, 4 and 5;

B is selected from —C(O)N(R h ) 2 —, —S(O) 2 N(R h ) 2 —, —C(O)—, —S(O) 2 —, —C(O)O—, wherein each R h is selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen; and

R 20 is selected from (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, (C 1 -C 6 ) alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen.

9. The method according to claim 8 , wherein the compound of Formula II is selected from:

2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl cyclohexylcarbamate;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)acetamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)isobutyramide;

1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl-2,6-dimethylphenoxy)ethyl)-3-phenylurea; and

3-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-1,1-dimethylurea.

10. The method according to claim 1 , wherein the compound of Formula II is selected from:

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3,5-di-tert-butyl-4-hydroxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-hydroxy-3-methoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(3-chloro-4-hydroxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-hydroxy-3,5-dimethylphenyl)-6,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(6,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)acetamide;

2-(3-chloro-4-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3-methoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6,7-dimethoxyquinazolin-4(3H)-one;

N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenyl)-2-hydroxyacetamide;

2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)acetic acid;

N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)-2-hydroxyacetamide;

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

5,7-dimethoxy-2-(4-methoxy-3-(morpholinomethyl)phenyl)quinazolin-4(3H)-one;

2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-hydroxy-3-(2-hydroxyethyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxy-pyrido[2,3-d]pyrimidin-4(3H)one;

5,7-dimethoxy-2-(4-(2-methoxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)- 5 -methoxyquinazolin-4(3H)-one;

(E)-N′-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenyl)-N,N-dimethylformimidamide;

2-(4-(benzyloxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methoxyphenoxy)acetic acid;

2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethyl-phenoxy)ethyl propylcarbamate;

2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethyl-phenoxy)ethyl methylcarbamate;

N-(2-(4-(5,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-4-methylbenzamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)benzenesulfonamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-4-methylbenzenesulfonamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-4-methoxybenzamide;

N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)benzamide;

1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-3-methylurea; and

1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)-3-(4-methoxyphenyl)urea.

11. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound selected from:

2-(3,5-dimethyl-4-(2-morpholinoethoxy)phenyl)quinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)quinazolin-4(3H)-one;

2-(4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetic acid;

2-(4-(dimethylamino)naphthalen-1-yl)quinazolin-4(3H)-one;

2-(4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide;

2-(4-(bis(2-hydroxyethyl)amino)phenyl)quinazolin-4(3H)-one;

2-(4-(5,7-dimethoxyquinazolin-2-yl)-2,6-dimethylphenoxy)ethanol;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylquinazolin-4(3H)-one;

5,7-dichloro-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

6-bromo-2-(4-hydroxy-3,5-dimethylphenyOquinazolin-4(3H)one;

6-bromo-2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

6-bromo-2-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)-3,5-dimethylphenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(pyridin-4-yl)quinazolin-4(3H)-one;

2-(4-(dimethylamino)naphthalen-1-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(dimethylamino)pyridin-1-yl)-6,7-dimethoxyquinazolin-4(3H)-one;

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-1-methylquinazolin-4(1H)one;

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-6-(morphoinomethyl)quinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6-methoxyquinazolin-4(3H)-one; and

5-hydroxy-2-(4-hydroxy-3,5-dimethylphenyl)-7-methoxyquinazolin-4(3H)-one,

or a pharmaceutically acceptable salt thereof.

12. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula II:

wherein:

X is N;

Y is CO;

R 1 and R 3 are each independently selected from alkoxy and hydrogen;

R 2 is selected from alkoxy, alkyl, and hydrogen;

R 6 and R 8 are each independently selected from alkyl, alkoxy, chloride, and hydrogen;

R 5 and R 9 are each hydrogen;

R 7 is selected from amino, hydroxyl, alkoxy, and alkyl substituted with a heterocyclyl;

R 10 is hydrogen; or

two adjacent substituents selected from R 6 , R 7 , and R 8 are connected to form a heterocyclyl;

each W is independently selected from C and N, wherein if W is N, then p is 0 or 1, and if W is C, then p is 1;

for W—(R 10 ) p , W is N and p is 1;

for W—(R 4 ) p , W is C, p is 1 and R 4 is H, or W is N and p is 0;

Z 1 is a double bond, and Z 2 and Z 3 are each a single bond;

with the proviso that if R 2 is alkoxy or hydrogen, then least one of R 1 and R 3 is alkoxy;

with the proviso that if R 7 is selected from hydroxyl and alkoxy, then at least one of R 6 and R 8 are independently selected from alkyl, alkoxy, and chloride;

with the proviso that if for W—(R 7 ) p , W is N and p is 0, then at least one of R 6 and R 8 is selected from alkyl, alkoxy, and chloride;

or a pharmaceutically acceptable salt thereof.

13. The method according to claim 12 , wherein the compound of Formula II is selected from:

3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

3-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one;

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one);

2-(4-hydroxy-3-methoxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(bis(2-hydroxyethyl)amino)phenyl)-6,7-dimethoxyquinazolin-4(3H)-one;

2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-6,7-dimethoxyquinazolin-4(3H)-one;

2-(4((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxypyrido[2,3-d]pyrimidin-4(3H)-one;

2-(2-chloro-6-methylpyridin-4-yl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-methoxy-3,5-dimethylphenyl)quinazolin-4(3H)-one;

2-(4-amino-3,5-dimethylphenyI)-5,7-dimethoxyquinazolin-4(3H)-one;

N1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)—N2-methylphthalamide;

2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

and 4-chloro—N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)benzenesulfonamide.

14. The method according to claim 12 , wherein R 7 is selected from an amino or an alkoxy selected from the group represented by Formula III:

wherein:

A is selected from O and N;

n is selected from 0, 1, 2, 3, 4 and 5;

B is selected from —C(O)N(R h ) 2 —, —S(O) 2 N(R h ) 2 —, —C(O)—, —S(O) 2 —, and —C(O)O—, wherein each R h is independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen; and

R 20 is selected from (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, (C 1 -C 6 ) alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen.

15. The method of claim 14 , wherein the compound of Formula II is selected from:

N1-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)—N2-methylphthalamide;

2-(4-(2-aminoethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one; and

4-chloro—N-(2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl)benzenesulfonamide.

16. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula II:

wherein:

X is N;

Y is CO;

R 1 and R 3 are each independently selected from alkoxy, alkyl, amino, halogen, and hydrogen;

R 2 is selected from —N—C(O)—R 18 , —N—SO 2 —R 18 , —CH 2 —C(R 18 ) 3 , —CH 2 —N(R 18 ) 2 , and —CH 2 —O—R 18 , wherein each R 18 is independently selected from alkoxy, alkyl, alkenyl, amide, amino, aryl, arylalkyl, cycloalkyl, haloalkyl, halogen, heteroaryl, heterocyclyl, and hydrogen;

R 6 and R 8 are each independently selected from alkyl, alkoxy, amino, halogen, and hydrogen;

R 5 and R 9 are each hydrogen;

R 7 is selected from amino, amide, alkyl, hydroxyl, and alkoxy;

R 10 is hydrogen;

each W is independently selected from C and N, wherein if W is N, then p is 0 or 1, and if W is C, then p is 1;

for W—(R 10 ) p , W is N and p is 1;

for W—(R 7 ), W is C and p is 1;

for W—(R 4 ) p , W is C, p is 1 and R 4 is H, or W is N and p is 0;

Z 1 is a double bond, and Z 2 and Z 3 are each a single bond;

with the proviso that if R 7 is selected from alkyl, hydroxyl, and alkoxy, then at least one of R 6 and R 8 is independently selected from alkyl, alkoxy, amino, and halogen; or a pharmaceutically acceptable salt thereof.

17. The method according to claim 16 , wherein the compound of Formula II is selected from:

N-(2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)acetamide;

2-(4-hydroxy-3,5-dimethylphenyl)-6-(morpholinomethyl)quinazolin-4(3H)-one;

N-(2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-6-yl)acetamide; and

2-(4-hydroxy-3,5-dimethylphenyl)-5,7-dimethoxy-6-(morphoinomethyl)quinazolin-4(3H)-one.

18. The method according to claim 16 , wherein R 6 and R 8 are each independently alkyl; and R 7 is selected from hydroxyl and alkoxy.

19. The method according to claim 16 , wherein R 7 is selected from an amino or an alkoxy selected from the group represented by Formula III:

wherein:

A is selected from O and N;

n is selected from 0, 1, 2, 3, 4 and 5;

B is selected from —C(O)N(R h ) 2 —, —S(O) 2 N(R h ) 2 —, —C(O)—, —S(O) 2 —, —C(O)O—, wherein each R h is selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen; and

R 20 is selected from (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, (C 1 -C 6 ) alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen.

20. The method according to claim 16 , wherein R 6 and R 8 are each independently alkyl.

21. A method for increasing expression of ApoA-I in a mammal comprising administering a therapeutically effective amount of a compound of Formula II:

wherein:

X is N;

Y is CO;

R 1 is selected from alkoxy or amino;

R 3 is alkoxy;

R 2 is selected from alkoxy, alkyl, alkenyl, alkynyl, amide, amino, halogen, and hydrogen;

R 6 and R 8 are each independently selected from alkyl, alkoxy, amino, halogen, and hydrogen;

R 5 and R 9 are each hydrogen;

R 7 is selected from amino, amide, alkyl, hydroxyl, and alkoxy;

R 10 is hydrogen;

each W is independently selected from C and N, wherein if W is N, then p is 0 or 1, and if W is C, then p is 1;

for W—(R 10 ) p , W is N and p is 1;

for W—(R 7 ) p , W is C and p is 1;

for W—(R 4 ) p , W is C, p is 1 and R 4 is H, or W is N and p is 0;

Z 1 is a double bond, and Z 2 and Z 3 are each a single bond;

or a pharmaceutically acceptable salt thereof.

22. The method according to claim 21 , wherein R 7 is selected from hydroxyl and alkoxy.

23. The method according to claim 22 , wherein the compound of Formula II is selected from:

2-(4-hydroxyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetic acid;

5,7-dimethoxy-2-(4-methoxyphenyl)quinazolin-4(3H)-one; and

2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide.

24. The method according to claim 21 , wherein R 7 is selected from amide and amino.

25. The method according to claim 24 , wherein the compound of Formula II is selected from:

5,7-dimethoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)quinazolin-4(3H)-one;

2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-morpholinophenyl)quinazolin-4(3H)-one;

N-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)-2-hydroxyacetamide; and

2-(4-(bis(2-hydroxyethyl)amino)phenyl)-5,7-dimethoxy-pyrido[2,3-d]pyrimidin-4(3H)one.

26. The method according to claim 21 , wherein R 7 is alkyl.

27. The method according to claim 26 , wherein the compound of Formula II is selected from:

3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)propanoic acid;

5,7-dimethoxy-2-( 4 ((4-methylpiperazin-1-yl)methyl)phenyl)quinazolin-4(3H)-one;

5,7-dimethoxy-2-(4-(morpholinomethyl)phenyl)quinazolin-4(3H)-one; and

2-(4-((4-ethylpiperazin-1-yl)methyl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one.

28. The method according to claim 21 , wherein R 6 and R 8 are each independently alkyl.

29. The method according to claim 21 , wherein R 7 is selected from an amino or an alkoxy selected from the group represented by Formula III:

wherein:

A is selected from O and N;

n is selected from 0, 1, 2, 3, 4 and 5;

B is selected from —C(O)N(R h ) 2 —, —S(O) 2 N(R h ) 2 —, —C(O)—, —S(O) 2 —, —C(O)O—, wherein each R h is selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen; and

R 20 is selected from (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, (C 1 -C 6 ) alkynyl, aryl, arylalkyl, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, and hydrogen.

30. The method according to claim 29 , wherein R 6 and R 8 are each independently alkyl.

Assignments (12)